Pre-exposure prophylaxis, or PrEP, is a strategy that involves use of antiretroviral medications (ARVs) to reduce the risk of HIV infection in HIV-negative people. PrEP is an HIV prevention strategy that doesn’t need to be used at the time of sex. This offers women and men an HIV risk-reduction option that can be used without negotiating with their partners.
Published: November 19, 2013
In July 2012 daily TDF/FTC was approved by the US Food and Drug Administration for use as PrEP for HIV prevention in HIV-negative women and men. Daily TDF/FTC has been proven effective at reducing risk of HIV via sexual exposure in heterosexual men and women, gay men and other men who have sex with men, and transgender women. The TDF/FTC approval marked the first time a drug was approved for reducing HIV risk via sexual exposure.
Table of Contents
•New Data on PrEP in People Who Inject Drugs
•VOICE Trial Results
•PrEP and Women in the US
•Guidance on PrEP Usage
•What PrEP Is—And What It Isn’t
•What We Know Now: Data to Date
•From Research to Rollout
•Challenges of Clinical Trial Design, Degree of Evidence and Recommendations in the Era of PrEP
Full text of article available at link below –